- Consumer Products
- Latest 74.865
- Currency US$
- Change -0.945
- Percent Change -1.247 %
- Volume 515,390
- Fri Jul 11, 2014 01:16 PM EDT NASDAQ data delayed 15 minutes.
12 months ended Mar 31, 2014.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||May 8||$-0.03||Aug 14||$0.27|
12 months ended Jul 11, 2014.
A look at major corporate events and financial announcements that are coming up.
About the Company
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices